{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:23Z","timestamp":1793320643018,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejca.2023.04.027","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:49:09Z","timestamp":1683452949000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":190,"special_numbering":"C","title":["Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types"],"prefix":"10.1016","volume":"188","author":[{"given":"Jammbe Z.","family":"Musoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7601-5450","authenticated-orcid":false,"given":"Corneel","family":"Coens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam A.G.","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9840-9266","authenticated-orcid":false,"given":"Yvonne","family":"Brandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3153-780X","authenticated-orcid":false,"given":"Mogens","family":"Groenvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6978-1587","authenticated-orcid":false,"given":"Hans-Henning","family":"Flechtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1899-5942","authenticated-orcid":false,"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9895","authenticated-orcid":false,"given":"Linda","family":"Dirven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfriede","family":"Greimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Pogoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Gamper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C.","family":"Sodergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap C.","family":"Reijneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.B.","family":"Taphoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine T.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.04.027_bib1","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.04.027_bib2","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.ejca.2005.05.007","article-title":"Health related quality of life outcomes in cancer clinical trials","volume":"41","author":"Bottomley","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.027_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2023.04.027_bib4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.027_bib5","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.04.027_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","article-title":"Methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clinic"},{"issue":"4","key":"10.1016\/j.ejca.2023.04.027_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jval.2020.11.004","article-title":"Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review","volume":"24","author":"Giesinger","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.ejca.2023.04.027_bib8","first-page":"555","article-title":"The interpretation of scores from the quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual\u00a0Life Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.04.027_bib9","first-page":"139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.04.027_bib10","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.04.027_bib11","first-page":"1713","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.04.027_bib12","article-title":"Establishing anchor-based minimally important differences (MID) with the EORTC quality of life measures: a meta-analysis protocol","volume":"7","author":"Musoro","year":"2017","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ejca.2023.04.027_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","volume":"23","author":"Dirven","year":"2021","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.04.027_bib14","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/hed.26363","article-title":"Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer","volume":"42","author":"Musoro","year":"2020","journal-title":"Head Neck"},{"issue":"12","key":"10.1016\/j.ejca.2023.04.027_bib15","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/codi.15295","article-title":"Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy","volume":"22","author":"Musoro","year":"2020","journal-title":"Colorectal Dis"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.027_bib16","first-page":"515","article-title":"Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core 30 scores in patients with ovarian cancer","volume":"159","author":"Musoro","year":"2020","journal-title":"Gynecol\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.04.027_bib17","first-page":"169","article-title":"Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma","volume":"104","author":"Musoro","year":"2018","journal-title":"Eur\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.04.027_bib18","unstructured":"Musoro\u00a0JZ,\u00a0Coens\u00a0C,\u00a0Fiteni\u00a0F, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with advanced breast cancer. JNCI Cancer Spectrum. pkz037,\u00a0https:\/\/doi.org\/10.1093\/jncics\/pkz03."},{"key":"10.1016\/j.ejca.2023.04.027_bib19","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1186\/s12885-021-08609-7","article-title":"Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials","volume":"21","author":"Gamper","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.04.027_bib20","doi-asserted-by":"crossref","unstructured":"Koller\u00a0M,\u00a0Musoro\u00a0JZ,\u00a0Tomaszewski\u00a0K,\u00a0et al. Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma \u2013 Interpretation guidance derived from two randomized EORTC trials. Lung Cancer,\u00a02022,\u00a0ISSN 0169-5002, https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.018.","DOI":"10.1016\/j.lungcan.2022.03.018"},{"key":"10.1016\/j.ejca.2023.04.027_bib21","unstructured":"Fayers\u00a0P,\u00a0Aaronson\u00a0NK,\u00a0Bjordal\u00a0K,\u00a0Groenvold\u00a0M,\u00a0Curran\u00a0D,\u00a0Bottomley A,\u00a0on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual. 3rd ed.\u00a0Brussels:\u00a0EORTC Quality of Life Group;\u00a02001."},{"key":"10.1016\/j.ejca.2023.04.027_bib22","first-page":"2","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J\u00a0Clin\u00a0Epidemiol"},{"key":"10.1016\/j.ejca.2023.04.027_bib23","series-title":"Triangulating estimates of meaningful change or difference in patient-reported outcomes: application of a correlation-based weighting procedure. Paper presented at:\u00a0Quality of\u00a0Life\u00a0Research","author":"Harper","year":"2018"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.027_bib24","first-page":"1249","article-title":"Test\/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire","volume":"13","author":"Hjermstad","year":"1995","journal-title":"J\u00a0Clin\u00a0Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.027_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/erp.11.9","article-title":"A point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ejca.2023.04.027_bib26","series-title":"Statistical power analysis for the behavioural sciences","author":"Cohen","year":"1988"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.027_bib27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","article-title":"A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale","volume":"57","author":"Eton","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.ejca.2023.04.027_bib28","first-page":"1753","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2023.04.027_bib29","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdq726","article-title":"Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients","volume":"22","author":"Maringwa","year":"2011","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.04.027_bib30","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s11136-021-03074-y","article-title":"Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: results from a randomized clinical trial","volume":"31","author":"Kawahara","year":"2022","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1016\/j.ejca.2023.04.027_bib31","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2016.6749","article-title":"Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials","volume":"3","author":"Basch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.04.027_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2307\/1914185","article-title":"Prospect theory: an analysis of decision under risk (PDF)","volume":"47","author":"Kahneman","year":"1979","journal-title":"Econometrica"},{"issue":"5","key":"10.1016\/j.ejca.2023.04.027_bib33","first-page":"1247","article-title":"How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales","volume":"32","author":"Cocks","year":"2023","journal-title":"Qual\u00a0Life Res"},{"issue":"Supp. 1","key":"10.1016\/j.ejca.2023.04.027_bib34","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1097\/MLR.0000000000001111","article-title":"Can methods developed for interpreting group-level patient-reported outcome data be applied to individual patient management?","volume":"57","author":"King","year":"2019","journal-title":"Med Care"},{"key":"10.1016\/j.ejca.2023.04.027_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s40271-022-00584-w","article-title":"Interpreting within-patient changes on the EORTC QLQ-C30 and EORTC QLQ-LC13","author":"Coon","year":"2022","journal-title":"Patient"},{"key":"10.1016\/j.ejca.2023.04.027_bib36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12955-016-0489-4","article-title":"Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain","volume":"14","author":"Giesinger","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ejca.2023.04.027_bib37","first-page":"128","article-title":"The minimally clinically important difference raised the significance of outcome effecs above the statistical level, with methodological implications for future studies","volume":"82","author":"Angst","year":"2017","journal-title":"J\u00a0Clin\u00a0Epidemiol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:55Z","timestamp":1760733655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":37,"alternative-id":["S0959804923002289"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Organisation for the Research and Treatment of Cancer (EORTC). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}